<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005403</url>
  </required_header>
  <id_info>
    <org_study_id>M21-410</org_study_id>
    <secondary_id>2021-002715-65</secondary_id>
    <nct_id>NCT05005403</nct_id>
  </id_info>
  <brief_title>Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab</brief_title>
  <official_title>A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Pembrolizumab or Budigalimab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer is a condition where cells in a specific part of body grow and reproduce&#xD;
      uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which&#xD;
      cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC)&#xD;
      is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck.&#xD;
      The purpose of this study is to assess adverse events and pharmacokinetics of ABBV-514 as a&#xD;
      monotherapy and in combination with Pembrolizumab or Budigalimab.&#xD;
&#xD;
      Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of&#xD;
      NSCLC, HNSCC, and other solid tumors. Pembrolizumab is a drug approved for the treatment of&#xD;
      NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called&#xD;
      treatment arms. The Recommended Phase 2 dose (RP2D) of ABBV-514 will be explored. Each&#xD;
      treatment arm receives a different doses of ABBV-514 in monotherapy and in combination with&#xD;
      Pembrolizumab or Budigalimab. Approximately 136 adult participants will be enrolled in the&#xD;
      study across approximately 80 sites worldwide.&#xD;
&#xD;
      Participants will receive ABBV-514 as a monotherapy or in combination with Pembrolizumab or&#xD;
      Budigalimab as an Intravenous (IV) Infusion for an estimated treatment period of up to 2&#xD;
      years.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">May 4, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AE)</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of ABBV-514</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Maximum Observed Serum Concentration (Cmax) of of ABBV-154.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Serum Concentration (Tmax) of ABBV-514</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Time to maximum Observed Serum Concentration (Tmax) of of ABBV-154.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of ABBV-514</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Terminal elimination half-life (t1/2) of ABBV-514.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-514</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Area under the serum concentration versus time curve (AUC) of ABBV-514.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antidrug Antibody (ADA)</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Incidence and concentration of anti-drug antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing Antidrug Antibody (ADA)</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Incidence and concentration of neutralizing anti-drug antibodies.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose Escalation: ABBV-514</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-514.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Dose Escalation: ABBV-514 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-514 in combination with pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514 + Budigalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with budigalimab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-514</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Part 1 Dose Escalation: ABBV-514</arm_group_label>
    <arm_group_label>Part 1 Dose Escalation: ABBV-514 + Pembrolizumab</arm_group_label>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514</arm_group_label>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514 + Budigalimab</arm_group_label>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514 + Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>Part 1 Dose Escalation: ABBV-514 + Pembrolizumab</arm_group_label>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514 + Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budigalimab</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>Part 2 Dose Expansion: ABBV-514 + Budigalimab</arm_group_label>
    <other_name>ABBV-181</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dose-escalation cohorts only:&#xD;
&#xD;
             -- Must have an advanced solid tumor who are considered refractory to or intolerant of&#xD;
             all existing therapies known to provide a clinical benefit for their condition.&#xD;
&#xD;
          -  Relapsed Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma&#xD;
             (HNSCC) dose-expansion cohorts only:&#xD;
&#xD;
               -  Must have histologically or cytologically confirmed advanced or metastatic NSCLC&#xD;
                  or HNSCC that has been treated with platinum-based chemotherapy and a programmed&#xD;
                  cell death (PD)-1 or PD ligand 1 (PD-L1) targeting agent (separately or in&#xD;
                  combination therapy).&#xD;
&#xD;
               -  Must have failed (or refused) treatment with available therapies known to be&#xD;
                  active for treatment of their disease.&#xD;
&#xD;
          -  Participants enrolled in dose escalation must have disease that is evaluable or&#xD;
             measurable per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1).&#xD;
&#xD;
          -  Participants enrolled in dose expansion must have measurable disease per RECIST,&#xD;
             version 1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.&#xD;
&#xD;
          -  Laboratory values meeting the criteria outlined in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relapsed Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma&#xD;
             (HNSCC) dose-expansion cohorts only:&#xD;
&#xD;
               -  Non-Small Cell Lung Cancer (NSCLC) participants with known EGFR mutations or ALK&#xD;
                  gene rearrangements are ineligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolina BioOncology Institute /ID# 232597</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 238332</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 238333</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 238840</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 238372</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Budigalimab</keyword>
  <keyword>ABBV-181</keyword>
  <keyword>ABBV-514</keyword>
  <keyword>KEYTRUDA</keyword>
  <keyword>Pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

